NanoTherm Ablation for Prostate Cancer

N/A

Waitlist Available

Research Sponsored by MagForce USA

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 months (+/- 1 month)

Awards & highlights

No Placebo-Only Group

Summary

This trial evaluates NanoTherm ablation, a treatment that uses tiny particles to heat and destroy small cancerous areas in the prostate. It targets patients with intermediate-risk prostate cancer who have small lesions in Gleason 3+4 disease. The treatment aims to offer a less invasive option compared to traditional methods like surgery or radiation, by using heat to kill cancer cells in a very targeted area. NanoTherm ablation uses magnetic nanoparticles to heat and destroy cancer cells, a method that has shown feasibility and good tolerability in recent clinical trials.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 months (+/- 1 month)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 months (+/- 1 month)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months (+/- 1 month) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Rate of Ablation Success

Secondary study objectives

Adverse Event Rate

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ablation ArmExperimental Treatment1 Intervention

Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.

Do I qualify?Apply below to find out